Dr. Christian Itin
pleasure Julia. review second It's of morning you progress XXXX. quarter joining all. to for our Thank you Thank my for to you, Good the us.
an which where ASCO the which complete interim acute quarter highlight. either remarkable well need any and our excellent in complete the presentation with up a lymphoblastic very persistent high-grade for recovery incomplete with with and we as XX%, profile additional hematological of treated patients came very X, on was at shown anti-leukemia with and Slide duration safety ORR, our productive tracked pivotal had XX%. The to patients data FELIX has we analysis, and in based remissions XX% seen cytokine EHA levels was adult Moving the second of from The study without in with data of or have leukemia. obe-cel syndrome ALLCARXX of profile, study low therapies. remissions release prior response the ICANS, long-term on relapsed/refractory
obe-cel-related follow-up filing FELIX outcome the several delivery delivery was robust is the planned obe-cel. to product Critical short to focus submitted our time, Next of with percentage abstracts vein week. high successful manufacturing patients with for of first the for dosed Key facility, with Nucleus. we this a with platform biologics quarter application of FDA authorization market on on of a completion is at of application the commercial XXXX. validation EMA now which track XXXX, the the call and end the license in with the of high and organizers the rate, ASH We're of manufacturing a study success for the
launch, centers. affairs, regulatory clinical of we're dossiers, and completion in with review, preparing the value critical the also program of towards actively medical activities progressing is for As underway obe-cel onboarding
a overview On the progress. Slide of pipeline X, we have short key
attractive across of DLBCL indications, obe-cel lymphoma, complete opportunity. In high the ALLCARXX patients. with in lymphoma B rates sustained we very level First, non-Hodgkin's to in we demonstrated an our remission study, metabolic high patients levels expand continue of in CRS non-Hodgkin's
confirmation dose profile ALL starting seen believe COGS, disease, and and decision and base, notably XXXX. to taken efficacy in well-differentiated established obe-cel Phase also patients, excellent in O have study the with we in which for to with will We translate SLE commercial develop obe-cel autoimmune have in we a well Hodgkin's safety B-cell-mediated together the start X attractive We into delivery expect opportunity. small and obe-cel our drive plus of on lymphoma manufacturing will a expansion autoimmune the early diseases, patients
clinical the ALLCARPALL obe-cel Looking the showing continues into peripheral quarter, was pediatric quarter, now beyond impressive and second second EBMT year. level updated a at complete remissions treated show AUTOX/XX favorable lymphoma patients in one meeting the very safety T-cell lifecycle, we AUTOX longer with profile. follow-up the of study in of an activity with and to Also, the presented sustained
and collaboration multiple finally, well expected myeloma in first MCARTY of planned Phase in AUTOXNG UCL, X the also And X is to for start the with progressing the the with study year. study, end Finally, in quarter. the data is AUTOX third neuroblastoma Phase in
the a Crabtree Financial our the wealth succeeding elsewhere, the more Iannone, science of than industry, and about had has as in is will further having & Turning the he of relevant that life Robert experience team We company the busy Rob Rob Company. call Directors quarter you quarter. Affairs. brings Pharmaceuticals immuno-oncology as time tell the the strengthening she company to of brings across process great CFO that, positioning had quick XX wide Rob to to a July, at worked of of phases long, sale call. in appointment, a announced as and Autolus Regeneron. member that Checkmate of how science in instrumental a had and products. product. as addition like we with Jazz life and development roles US Sciences, to who and of diversified programs a joined in team. a Hersberger Senior broad oncology Swiss we're areas very to Chief remarkable Moderna, the and brings Officer. range In and later regulatory in the review and Board as us really we the Rob appointed out development, we're Autolus Rob where same career across level of today operational private June. where Dr. the affairs, TargImmune, Immunomedics, Prior years long Slide Medical and therapeutic the a served him At experience on through a the Officer. at joined key driving a and Medical be She medical experience board start with of announced been additions the going and oncology great with and Dolski Veronica the Chief Autolus leadership range obviously is we from was including in of a to as during is more obviously Merck X executive development, AstraZeneca, served Rob's Lucinda a Pharmaceuticals, from very as a introduction second also Autolus very experience give financial Vice roles the bit I'll announced and President, ask second a Veronica Human to Genome joined to I'd Rob Amgen. Dr. key
hematology the the was of development at oncology AstraZeneca, And range product global prior During Veronica Lumoxiti. the involved franchise she time leader a over as of that, Roche, wide affairs Calquenceand both for at served she programs. head to global where years for of in also medical a was her the
Genome to heading for companies, as therapy consulting well experience Project at Management. and Vice clinical as facility has program, Nucleus of product. supported promoted and Finally, leading record and in biopharma of in stage at Miranda programs the recently then Program Autolus, over Autolus, obe-cel SLE in Miranda the program. Neville Senior engineering the BENLYSTA Prior operations. was like years the large Portfolio Autolus’ President, to product, projects manufacturing Prior program companies in Head delivering others. resulting has President, Management, Genome And XX Sciences, Miranda Miranda successful regulatory various commercial capital ran launch obviously Miranda to served gene the of Miranda at through time. the obe-cel roles up most particularly led BLA, Human Vice management, capital approval project as Sciences several and Human and projects
very of and respective continue in So, will already, in experienced lot a future. impact significant we're contributions set their and the a of all having of fields, team with are the a expanding obviously them industry leaders
X. that, Slide I'd moving With to like we're actually switch to to Obe-cel, over and
the would key take Here, quick a the really like I that data at from data. to ASCO you the both FELIX give opportunity as of EHA to and at presented summary as well we update
for at an patients endpoint gone secondary is extensive through you negative looking of had then based being we're ability - that survival therapy to actually well response, overall The enrolled duration for and we CRS extensively this been and and response that that patients on the overall CRis, study. remember, MRD relapsed/refractory prior were survival, we're event-free lines at primary looking obviously convert eligible as to rate look patients into as endpoints the status. of As
enrolled enrolled can also and the dosed you the patients slide so product. see infused between characteristics were have and actually the enrolled key we the the kind of the in XXX We Now, of study. what patients infused XX% patients the And XX, with were. in difference
the a advanced characteristics clearly Now, as population. baseline when indicated, at are we patient look these very
types certainly in between level somewhat When chromosome-positive age look We that’s have years, balanced well and older type at we've ALL, of gender Philadelphia usual what the patients the population obviously and prior patients. prior in with. work an have not easy to We seen average you relapsed/refractory studies XX therapies. somewhat of of above see of of
the their patients patients Extramedullary had to have proportion to point very significant out be difficult think and of to which to a also and we that treat high levels bottom what manage. at in the burden tumor like had I that is disease, I'd of obviously known marrow, are did
XX, is rate. overall Moving response to Slide this the
very but complete negative had rate we achieving XX overall patients response the see, XX%. at and high an can also XX% MRD of Cri, you have an we achieved four. a with the status the of patients As of minus not CR XX% remission, a to seen just level of sensitivity
we part bit curve still need patients look obviously of to study what still in the tells you we Now, see ongoing of very at and of curve, is this had for responders of a follow-up that for tracks And of you can terms At you is the upper still quite curve with which there's fully also point, observation of median part stabilize. remission. there response, the actually XX% earlier with in of this this see the X.X are the and that can number that this a nicely significant early But a when to overall follow-up, prior. expected in we seen duration months.
sub-analysis into driving patients Now, out, disease, here. What the look XX, response on have before, like tend key indicated into Slide we outcome, the see overall rate, marrow. number when more have impacting the have disease kind very are to of I'd - high of to do sort of what's Extramedullary as levels in bit as a we a obviously that drivers of poor or point that patients
that in the whereas range of burden In you that if XX% of level and fact, burdens of any the in a see the response disease fact, between you reduction somewhere below, patients about have and in in were XX%, tumor with more to the marrow, patients XX%. overall below than range XX% marrow, have XX% rate
very either lines that if also surprise less or that therapy had less than prior significant a prior impact that I therapy, a patients prior obviously not obviously before. that pointing think some to worthwhile out had of number you And they can and been we overall, tend Ino on limited to therapy. exposed do well blinatumomab of see have patients it's
However, also overlapping. are those
confidence So, interval, from differentiated. a not clearly
So, moving with to that, safety.
release on see specifically Slide have toxicity it's by when obviously ICANS, can as and and have product. observed. we summary a measured you remarkably quick the cytokine neurological We on safe toxicities remarkable we think syndrome you As see that overall I looked immunological XX, for that
therapeutic of any blincyto. the look to about had that including that therapies see high-grade any patients at overall T-cells. below we ICANS, had I the other we we X%, redirecting grade think, the that X% is ICANS is When low. are is experienced utilizes the T-cells, level of also approach that which very low It's CRS higher CRS, other, level, which compared also On of
the difference release that of see cytokine see burden tumor burden have I think but of syndrome. impact ICANS, do a see that on we more somewhat we that of ICANS, On on elevated. tumor the don't XX% overall burden, patients ICANS are terms an than you much in tumor can on
that patients ICANS. of have We about have XX%
you're six If was a patients XX%, out at which ICANS, of time most remarkable of low tumor was lymph high-grade to that experienced XX, a the more was below total had What depletion. high-grade you that actually have probability of the the the experience very patients burden quite a of XX% seven of than ICANS.
information they're could ahead patients and ride. position So, very in risk, this of the (affect dosing, on highest also actually being an to how therapy that everything actually else basically is XX%, dosing do disease patients rather the for going where to and patient control and and in this a to expect after to excess of finding what gives forward prior contain a you group physicians of bridging than towards) taken themselves therapy the the frankly manage which of that's you that's the the have important still
Slide of properties The is key one of to in we've a to engagement only the the toxicity us very killing into actually at get that as of design obviously proliferate. kill the been they're a with at obviously allows have XX, unique for also rapid can And action into and looking to obe-cel that we as rapid you the of is product again, that rapid those very signal to back which mode, target the unique cycling give action. much, very physiological see, back design. actually they as they T-cell occurred, then recognition, has you it recycle not parameters But in a cells, do a one remember, after that the a ability behavior moving is continue patient. Now, lower and serial level strong actually much kill, an of disengagement overall, cells is a has that
gives left massive hand T-cells the And of nicely do a the peak CAR that in in side this so, what very very the you ALLCARXX of area on nicely see is study, XX, first the Slide that things our which enormous formed CAR matching. curve very all see That matches T-cells prior under look study. When we of fact our one we of the of the us matches peak also across expansion XX or patients we nicely in number the total for which time. expansion vivo, on over have seen the at with days,
with experience. at If level matching over you sustained half-life, as CAR do ALLCAR see nicely And we the before, look T-cells of a very time. prior our we've seen
in quick And ALLCARXX see to T-cells that persisting plot the sustained any behavior therapy, this levels of CAR also the the that but And similar the that And top hand we is rapid on important side, T-cells. those here we the look had is reminder, without all the very can patients see because we the swim in CAR additional right this on - on as all to you up patients which years of at what was go of you patients can ALLCARXX Slide the then of four long-term XX, expansion, did remissions time. are sustained study, the as left-hand over a study. part observe side observation had
terms we believe of track high confidence seen the in study gives on tracking So, ALLCAR in follow-up of that right have us we replication study in having our of a well. the seen cellular a longer-term actually we're properties as what degree the FELIX a
we the obviously able with conducted slide the pandemic. that peak go onto the on to We was a study. have seen were Moving this in not excited study we to the outcome backdrop, of as which see XX, Remember, summary we're this very patient through done can also it's And into patients reflected remotely. of range like the and the wouldn't see, risk a wide FELIX normally population, as extraordinary the study. in with actually sites. was factors, have you Everything studies recruited
So, time reliably really ability is the and as so further in obviously what of safety in we're at in at the talked a us to our to as patient with look both seen in real-world here. engraftment on we with of and on And product that we've be the what patients, very have and also seen the gives the we study. of in - about, we population product, a level of these property obviously experience then follow-up treated a well for our we've we ability our confidence have lot much of us high the the but quality see with prior lot before, deliver tracking When analysis that as efficacy, which confidence just to the critical. program, consistent outcome, gives
minutes to like to success XX. two, slide want talk some just product are on spend just three I'd critical briefly manufacturing, I about of to a what supply. on And factors Now, moving the
actually The first with only are these bone and because patients in is, actually with a very blood. marrow, actually that basically gets leukemia, burden have disease when the you challenging not also into blood leads in high of material, have dealing with acute you disease but starting start also their very the do to many patients tumor
can your the manufacturing be you’re because an materials. when up you handle very to to you wide patients XX% of in that cells cells. able leukapheresis, rid cells be to and means collecting the So, starting complex starting get to blood have about you has leukemic which material from even a imagine, of manufacturing, incredibly and And of process first challenging cells have a you those range the you think can before cells that that's you difficult as have predominant can where collect,
delivery that robustness is a achieve we manufacturing required level process the for product time of lot optimizing So, product reliable of the here. spend actually to
to to you a if overall very you take allows time, and production need times. which that the means analytics the have allows part release batch product in to be than release That we're allows also which what it what that very, product. turnaround time aspect time, you you leads consistent that actually of enclosed a that consistent actually need is reduction you typically a in actually time, a is very costs and - for particular us takes in people to lower room And manage have space. fully those to leads that then to other the turnaround overall actually in consistent clean system that in you has full a that a see environment to a rooms. record fact us to operating massive and actually with The our the massive with grade do consistent is you the a important out is operate get And
steps actually also involved. but on whole simplifies that's it also costs approach costs, impacting which also directly substantially. decreases level And semi-automation, much to allows because So, reduces with actual also And has handling it but increases robustness, you cost. build of the it running that, semi-automated a less the
Now, They and shouldn’t you people The operate in people point critical hire the exist. market. actually our not build people have at a to train. you piece this are do actually here, we not people in that importance the and that manufacturing facility here are of to from have you underestimate I the the think Stevenage, facility like can
have You train actually to them.
this of are of this the operation, type highly our is make full-fledged of extremely sure that motivated actually skilled fully an that continuous capable, do workforce a operators an program to trained we the creating have is important. training and type and establish things critical. And a to then is absolutely deliver outcome. culture And one to actually of trained, improvement key So, fully
the operation, serve a to you're reduce in. opportunity efficiency, of deliver US processes the actually creates critical outstripped also to the of completely that increased decrease ability to seen in in us to the all a you really cost as only that that turnaround goods every And This that we by something lot actually continued over in the with from the launch is gives to of at and that not the that frankly, is capacity ultimately well to facility And but in launch design Europe we've large allows problems, it's be and launching available that the finally, of get and translate, market one of from of to been If product. improve issues treat a time. time, in then of scale why able chose as have to we of disappointment, will that, actually right. one And that's them. that was robustness, facility the launch relapsed/refractory important thirds and or a you And you two that number demand. have have patients which spaces single steps, plan lot the
those important aspects. are So,
want don't you You much the have also over-design or too if to high, actually because over-engineer go capacity, excess you too capacity.
significant to very a cost impact have on adversarial goods. You
So, whole kind which of and moving which XX, actual reliable the with robust the do terms in with on to already workhorse aspects be the equipment, slide matter have are Prodigy frankly, manufacture. I and really proven series of Miltenyi the to that, working the that of mentioned We're we machines, product. extremely
You do transduction chart, chose the delivery part as DHA the batch to manufacturing manufacturing to is ESCO actually field. present of every see because our time. you in rate, at efficiency for frankly important. the the what of to chose quite and an also area think part lower That's is in in unusual we study. can important the extremely to the the And at way that manufactured why and on rate we see pivotal looking presentation the this actual success show where I confidence this single data And is consistency the
year. And clean went project the in in We groundbreaking facility. moving file first we We're this run ‘XX We room evaluation BLA brief the end November facility, the time. on It facility. this was get a by XX, November the to very Now built up ‘XX. well and project. in this of a the of manufacturing complete a Slide expect unusual to or word from to product track on record manufacturing running just commercial to
into the timeline XX groundbreaking filing, and that actually So, build, facility so submit registration. roughly obviously to you the the from And of that includes all for shape validation can of that all of months. full BLA getting
So, really it we've There's at ultimately to do what's it's important infrastructure, just people actually us as is quite this be et areas different a facility that back type than without lot through I level project. flow what’s can operate also on temperature, done, it what that goes it of high right-hand to that gets and done team, normally the cetera, on remarkable been demonstrate can then But the is breaking the of to equipment of facility. ability, actually you the on frequency goal-setting. goods, side, and either but a think or the of pressure, see on materials, differently the the
which from running point et hand So, of in conducted that pressure system, what at there. improving Prodigy side keep you every of you in have parallel room, identify the the us pressure flow, machines you cetera, time challenge or see maximal leads to one and test, actually the is and the that the you - stress see et second of the literally cetera, use a facility, flow, good, maximal really people ability address to issues actually amount materials, on the right where then quarter and on gives facility, in in we capacity obviously in the maximal where in through
operations been successful it's very that had. a we So,
range time I'd the the here through all our obviously the logistics like during And challenges delivery was is make that pandemic to comment XX days. and final
accelerate set that but operating were pivotal to effect all I'll and at has which mention down of XX and at do actually that a launch. time days next model of to the as of launch, also were implemented that on come release expect the assays We part will the implemented the to that go commercial full to actually slide, to on and and with allows study
sort to then lot HDS of focus the launch, have things needs working to completion on the file next BLA core to So, be approval, look prep, of is One obviously has preparing ready. commercial to the side, on. for on that number XXXX the obviously to data a path to also, really on need for affairs the have be talked and in work of in we a And the when there in a year we all focus dossiers that end medical in Slide the which obviously place, Manufacturing the side commercial XX, are actual and we to early you need which commercializations then Europe. have put to of a going together. execution, of considerations particular, really year central needs Expect need activities the substantial and into amount obviously with lead and then focus by already. side. on to are and launch, we ongoing time, and the application European It really obviously obviously around onboarding, about it
to that Health And the to allows did have Slide it as components infrastructure the because our And we our selected us supported Now, need XX, is the is one partner. specific be to that important allows of actually partner. things fact of by us Cardinal of that we our some commercial on, aspects supplied we distribution on bespoke sort report US to on activities that the and have of do. what focus
- on move actually directly change the an but a then there forth, with actual be government. be the and it be able be released them actually goes probably to the and ship before really US, obviously model is while where the the distributor think way the from there to because processing and on what's our technically prior us has has time that obviously then, is the get But to in they're manufactured they're to invoice sure of that patients also center help that slide. still perspective time, moved in reduction center, in time. to to custody, delivery to released, from ship that custody center. which Same the fulfilled, from going will from for are my and an full physically activities. And the to depot to operational release important key to products allows can and checked of are make product out then Cardinal order-to-cash contributors fully has be important the related fully but to the ultimately us areas be support where delivery cut will success is that depot these of we're range those the obviously range is and has I actually us. the to still to distribution parallel can in some as how one And moving soon There UK not as of So, are the pointed ultimately time everything of is reporting moving to that the more US us is be And generated. I products
to product the Now, a track. and not go that focus it when opportunity obviously in Obviously, look the that What just where from an and slide lot we obe-cel approach primary which see we for is is is is are there from ALL, combined is XX in XX myeloma, a well products. AUTOX/XX, ALL loss as an of leading a directions. on about dual-targeting single is, way approach in receptor. chimeric of franchise management opportunity obe-cel, summarizes but we that of with lifecycle company, quite on follow-on possibly targeting Slide think relapses obe-cel the and also CDXX follow-on products the but a very a then it CDXX obe-cel multiple that actual we is but for do several in It's see we second this approach has BCMA here? disease, sensitive The two is antigen. addressing also perspective, true a And dual-targeting driven around itself, by is And two autoimmune o for for of the challenge a antigen actually with develop obe-cel.
cells, tackle give levels well sensitive products that and which on trying cells, fact, CARs and make down-modulate that myeloma, believe to obe-cel, of efficient here of in patients, analyze be XX, the expression. is of low. multiple see extremely taking with do done those BCMA we're Quite out. and as can they're best-in-class cells, CDXX a XX, not the per make XX, many receptor business, can in that CAR to receptors that sure in two sensitive similarly, XX CDXX the sort and we even to So, highly additional a can of those tailored recognized per very activity is And have that if that very chimeric from combining XX, basically but expression CDXX-expressing thousands, obviously receptors XX be what us It efficiently requires cells to cell. low sure CDXX engagement be taken we've cell, for we're you when in they have it cells expression, actually you actually against CAR, CDXX the we are very those antigen the
those And obe-cel. also of combining that CARs and So, a on we're optimization us hemato-oncology of applications looking that autoreactive the on where both applications but the gives gives set interesting And the rid choose C with CDXX done of plasma B-cell-producing well, side CAR. also from autoimmune was can of here, we're to we've very that of similar both we side, the with get products CAR on side sort cells. us as the to it what
obe-cel. setting, has Obviously, end slide many you've achieve keep updating data is us This is a extended good of period we're also those that as safety XX. be CRSs in as see it levels next in we a been Very which patients obe-cel sustained to used respective the believe responses And all this on before, seen well. slide where of what dosing We'll and have the something seeing is to single clinical obviously data. outpatient moving last quite so of persistence. remarkable. non-Hodgkin's actually what indications, Slide a very patients The - of which non-Hodgkin’s of Also, published hasn't at metabolic interesting, settings these DLBCL field. the summarizing and consistent relapses level activity. year. gives in been them as excellent seeing quite with non-Hodgkin that indications of dose actually should with we're of So, in just do high in Almost that sustained a lymphoma, all And level obviously have obviously time. we we're reminder, safety over is profile very far, significant and activity a a no is across actually the and allow the
cleared CDXX really autoimmune Moving have Many you Erik seen we word of quick for the set pioneering because see was the autoimmune B-cell remarkable over study work well month, disease. patient to The that clearance related the opportunity the by lost antibodies, next XX. time. approach then we very the obviously within papers A typically Andreas of observed obe-cel outcome at autoreactive slide, short as was and as what (indiscernible) Slide mediated the on time. published diseases. that was clearly and mediated in the an of cells from several underlying that with expanded initial period refractory that as within a now, antibodies producing sustained about looked a additional is of quite utilizing CAR patients got into basically B-cell the and The Mackensen in Erlangen, University SLE actually in
patients. did composite to consequence autoreactive a So, that very antibodies, are as scores of these the baseline. from the of and And high went basically refractory recover removal patient
program. So, antibodies. think Miranda I in the the the that remarkable, ran mentioned very very field I BENLYSTA monoclonal the outcome from we've different anything seen based on was fact
et positioned the look bit believe in We and at data well the a can obviously that, the because of companies seen B-cell-mediated. there's CAR the autoimmune outcome, This probably as our of the on with a CDXX within extremely have, also active based quality that different cetera. we quite today, we product start do so is is So, our as diseases, safest most of number actually company tell, understanding a we to have we're and you've far of business.
products an of base, at and goods. attractive We a cost we manufacturing and deliver have reliably also have these ability to commercial
of position the are a of all think components think CAR CDXX to related I diseases. program or these I B-cell-mediated incredibly important if autoimmune any you want
out study with with that basis agency. as We will dose the a we a SLE and study. then in confirmation use of do the pivotal the to discuss that We'll will start design patients,
So, that's program. are where we with the
here. we're next to the opportunity early really get obviously expect started in We patients, and year excited, dosing about
therapy that CDXX-mediated patients find quick this that an looking Just actually then patients activity, mitigate relapsed tested CDXX for AUTOX/XX clinical two us as obe-cel of programs as Kymriah And disease. profile. a CDXX Obviously, the beyond safety a are reminder of mediated to well as gives product - I way we've excellent mentioned are loss including ineligible very we had relapses. with a that on again other in Kymriah, AUTOX/XX, good in after show the negative franchise. to that high level can activity sustained level
it investment multiple think, product, the is, provides obviously, this So, program I sort for do what and to opportunity in doing we the AUTOX of that Also, myeloma. targeting forward. an is program expect going interesting clinic. is
potentially allow is cells plasma multiple the plasma to BCMA, CDXX have first positive. data fact also Dr. for cells been in on are at just form are end Hopkins, having clearly get remission and the was postulated that but driven obviously the in are should is through expression that SLE, myeloma. following the that's expect CDXX believe mid-XXs a also a that that while We has the positive field, sustained year. but sort been those there's cells has an that that hypothesis a give more and one the of at actually ability principle very by B-cells of now a the and CDXX That's that of cells we immunity are There that us with a debate chance going hypothesis And us CDXX Matsui see cells also also side. the in the fact, it's actually to we that data good component deeper in at and that of presence low design been in conversation driving Johns the on of
actually interested we obe-cel, of were AUTOX, seen really that in to data publish an - in the sort we that induce finally they data Now, of were at reviewed crossed working there's over what meeting in The an of those year, well. have see data, sustained one that now and confidence lot fact, that clinical and that provided of with that we’ve journal obviously to beyond in Lugano can we're seratherapy. on us looking a peer remissions induce where patients the effect And able have in that starts we two And update excellent on benefit the were of is the the have data also the we're the to data. sort patients on time. obviously key more Lymphoma to as these continuation give a we moving complete
data has do gives beyond data on collaboration opportunity slide us pipeline clinical is UCL been actually based running, Now, significant to when programs investment decisions making collaboration moving for be just on of on we obe-cel see the our quickly Slide translational can the work of through XX there which be we're generate translate beyond confidence are provide also the and initial really we're sort and we field, and program indications, to not and clinical an preclinical do which ability and as we a decisions a of what beyond have obviously unfortunately in you broader patients. on the really outcomes so with do in to can that based going a amount terms successful believe of the to collaboration, lot data, in this very into doesn't future
the would results. to that for I financial So, like to hand with over Lucinda
